Pamela Munster

Pamela Munster

UNVERIFIED PROFILE

Are you Pamela Munster?   Register this Author

Register author
Pamela Munster

Pamela Munster

Publications by authors named "Pamela Munster"

Are you Pamela Munster?   Register this Author

100Publications

5560Reads

20Profile Views

Reply: Strategies to Prevent Cardiotoxicity.

J Am Coll Cardiol 2019 Oct;74(13):1737-1738

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.07.047DOI Listing
October 2019

A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600 mutant advanced melanoma.

Pigment Cell Melanoma Res 2019 07 13;32(4):603-606. Epub 2019 Apr 13.

UCSF Hematology and Oncology, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12777DOI Listing
July 2019

Maintenance Lenalidomide in Primary CNS Lymphoma.

Ann Oncol 2019 May 2. Epub 2019 May 2.

Helen Diller Family Comprehensive Cancer Center, UCSF.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz142DOI Listing
May 2019

Coil combination methods for multi-channel hyperpolarized C imaging data from human studies.

J Magn Reson 2019 Apr 1;301:73-79. Epub 2019 Feb 1.

Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmr.2019.01.015DOI Listing
April 2019

Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.

J Clin Oncol 2018 07 2;36(19):1981-1990. Epub 2018 May 2.

Matteo Lambertini, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Halle C.F. Moore, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Robert C.F. Leonard, Imperial College, London; Richard A. Anderson, University of Edinburgh, Edinburgh; Douglas J.A. Adamson, Ninewells Hospital, Dundee; Gianfilippo Bertelli, Sussex Cancer Centre, Brighton, United Kingdom; Sibylle Loibl, Keyur Mehta, and Sabine Seiler, German Breast Group, Neu-Isenburg; Bernd Gerber, University Hospital Rostock, Rostock, Germany; Pamela Munster, University of California, San Francisco, San Francisco, CA; Marco Bruzzone, Francesca Poggio, Marcello Ceppi, and Lucia Del Mastro, Ospedale Policlinico San Martino; Francesca Poggio and Lucia Del Mastro, University of Genova, Genova; Luca Boni, Azienda Ospedaliero Universitaria Careggi, Florence, Italy; Joseph M. Unger, SWOG Statistical Center and Fred Hutchinson Cancer Research Center, Seattle, WA; Susan Minton, Moffitt Cancer Center, Tampa, FL; Kathy S. Albain, Loyola University Chicago Stritch School of Medicine, Maywood, IL; Amy Cripps, Nexgen Oncology, Dallas, TX; and Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.0858DOI Listing
July 2018

Host histone acetylation unlocks HDAC inhibitor potential.

Oncotarget 2017 Dec 13;8(63):106161-106162. Epub 2017 Nov 13.

Pamela N. Munster: Department of Medicine, Division of Hematology and Oncology, Helen Diller Family Cancer Center, University of California, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22422DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739717PMC
December 2017

HDAC inhibition potentiates immunotherapy in triple negative breast cancer.

Oncotarget 2017 Dec 12;8(69):114156-114172. Epub 2017 Dec 12.

Division of Hematology and Oncology, University of California, San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.23169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768393PMC
December 2017

Interest in initiating an early phase clinical trial: results of a longitudinal study of advanced cancer patients.

Psychooncology 2017 Oct 20;26(10):1604-1610. Epub 2016 Jun 20.

Philip R. Lee Institute for Health Policy Studies and the Department of Anthropology, History, and Social Medicine, University of California, San Francisco (UCSF), CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pon.4179DOI Listing
October 2017

Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer.

Plast Reconstr Surg 2017 Sep;140(3):537-544

San Francisco, Calif. From the Division of Hematology and Oncology, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PRS.0000000000003579DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604844PMC
September 2017

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.

Blood 2017 06 8;129(25):3294-3303. Epub 2017 May 8.

Section of Bone Marrow Transplantation & Leukemia, Division of Oncology, Department of Medicine, Washington University, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-09-740787DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482100PMC
June 2017

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.

J Clin Oncol 2017 Jan 21;35(3):352-360. Epub 2016 Nov 21.

Renata Ferrarotto, Yoshitsugu Mitani, Lixia Diao, Irene Guijarro, Jing Wang, Patrick Zweidler-McKay, Diana Bell, William N. William Jr, Bonnie S. Glisson, J. Jack Lee, Andrew Futreal, Adel K. El-Naggar, and John V. Heymach, University of Texas MD Anderson Cancer Center, Houston; Michael J. Wick and Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Ann M. Kapoun, Leonardo Faoro, and Jakob Dupont, OncoMed Pharmaceuticals, Redwood City; Pamela Munster, University of California San Francisco, San Francisco, CA; and Gail Eckhardt, University of Colorado Denver School of Medicine, Denver, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.5264DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5456373PMC
January 2017

Effect of Temporary Ovarian Suppression on Chemotherapy-Induced Amenorrhea, Pregnancy, and Outcome.

Authors:
Pamela N Munster

JAMA Oncol 2016 08;2(8):1089-90

Division of Hematology and Oncology, University of California, San Francisco2Helen Diller Family Comprehensive Cancer Center, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.0614DOI Listing
August 2016

Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.

Epigenomics 2015 ;7(4):641-52

Department of Medicine, Hematology/Oncology Division, University of California, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/epi.15.16DOI Listing
June 2016

Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.

Immunotherapy 2016 06;8(6):705-19

Department of Medicine, Division of Hematology & Oncology, University of California, Room A722, 1600 Divisadero St, Box 1770, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2016-0014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705793PMC
June 2016

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

Breast Cancer Res Treat 2016 Feb 13;155(3):521-30. Epub 2016 Feb 13.

Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3701-7DOI Listing
February 2016

A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.

Clin Cancer Res 2015 Dec 17;21(23):5235-44. Epub 2015 Jul 17.

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0180DOI Listing
December 2015

Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.

Cancer Discov 2015 Oct 24;5(10):1040-8. Epub 2015 Jun 24.

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California. Department of Medicine, University of California, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-15-0274DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592417PMC
October 2015

More Options for Fertility Preservation for Patients With Cancer.

Authors:
Pamela N Munster

J Clin Oncol 2015 Aug 22;33(22):2413-5. Epub 2015 Jun 22.

University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.9304DOI Listing
August 2015

Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer.

Breast Cancer Res Treat 2015 Aug 25;153(1):173-81. Epub 2015 Jul 25.

Department of Medicine, University of California, 1600 Divisadero St., Box 1710, San Francisco, CA, 94115, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3511-3DOI Listing
August 2015

Ovarian protection during adjuvant chemotherapy.

N Engl J Med 2015 06;372(23):2268-9

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1504241DOI Listing
June 2015

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

J Clin Oncol 2015 Mar 20;33(9):1060-6. Epub 2015 Jan 20.

Adil I. Daud, Michelle T. Ashworth, Alan P. Venook, Jennifer A. Grabowsky, and Pamela N. Munster, University of California, San Francisco, San Francisco; Jonathan W. Goldman and Lee S. Rosen, University of California, Los Angeles, Santa Monica, CA; Jonathan Strosberg and Gregory Springett, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; David Mendelson, Pinnacle Oncology Hematology, Scottsdale, AZ; and Sabine Loechner, Frances Shanahan, David Parry, Stuart Shumway, Tomoko Freshwater, Christopher Sorge, Soonmo Peter Kang, and Randi Isaacs, Merck, Whitehouse Station, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.5027DOI Listing
March 2015

Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies.

Cancer Chemother Pharmacol 2014 Aug 17;74(2):359-65. Epub 2014 Jun 17.

Department of Medicine, Division of Hematology and Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, San Francisco, CA, 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2510-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5257275PMC
August 2014

New protein kinase inhibitors in breast cancer: afatinib and neratinib.

Expert Opin Pharmacother 2014 Jun 30;15(9):1277-88. Epub 2014 Apr 30.

University of California , 1600 Divisadero, San Francisco, 94143, CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2014.913570DOI Listing
June 2014

Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.

J Clin Oncol 2014 May 7;32(14):1472-9. Epub 2014 Apr 7.

A. Jo Chien, Pamela N. Munster, Michelle E. Melisko, Hope S. Rugo, John W. Park, Andrei Goga, Glenna Auerback, Elham Khanafshar, and Mark M. Moasser, Helen Diller Family Comprehensive Cancer Center; A. Jo Chien, Pamela N. Munster, Michelle E. Melisko, Hope S. Rugo, John W. Park, Andrei Goga, Glenna Auerback, Elham Khanafshar, Karen Ordovas, and Mark M. Moasser, University of California San Francisco, San Francisco, CA; and Kevin M. Koch, GlaxoSmithKline, Research Triangle Park, NC.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/04/09/JCO.2013.52
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.52.1161
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.52.1161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017711PMC
May 2014

Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt.

PLoS One 2013 9;8(7):e68973. Epub 2013 Jul 9.

Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0068973PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711340PMC
February 2014

Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma.

Clin Cancer Res 2014 Feb 4;20(4):1029-41. Epub 2013 Nov 4.

Authors' Affiliations: Division of Hematology/Oncology, Genentech, South San Francisco; Helen Diller Comprehensive Cancer Center; and Department of Radiology, Laboratory Medicine, University of California, San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0474DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944388PMC
February 2014

Histone deacetylase regulation of ATM-mediated DNA damage signaling.

Mol Cancer Ther 2013 Oct 12;12(10):2078-87. Epub 2013 Aug 12.

Corresponding Author: Pamela N. Munster, Division of Hematology and Oncology, Department of Medicine, University of California, 1600 Divisadero, Room A719, Box 1711, San Francisco, CA 94143.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-1242DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821775PMC
October 2013

Fertility preservation and breast cancer: A complex problem.

Authors:
Pamela N Munster

Oncology (Williston Park) 2013 Jun;27(6):533-9

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA.

View Article

Download full-text PDF

Source
June 2013

The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors.

Breast Cancer Res Treat 2012 Aug 15;134(3):1327-35. Epub 2012 Jul 15.

School of Medicine, University of California, San Francisco, 1106 Stanyan St., San Francisco, CA 94117, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-012-2150-1
Publisher Site
http://dx.doi.org/10.1007/s10549-012-2150-1DOI Listing
August 2012

Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy.

Breast Cancer Res Treat 2011 Nov 5;130(2):437-47. Epub 2011 Feb 5.

Division of Hematology and Oncology, University of California, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-011-1364-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760725PMC
November 2011

Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.

Expert Opin Investig Drugs 2011 Nov;20(11):1565-74

University of California, Department of Medicine, San Francisco, CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2011.617740DOI Listing
November 2011

Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance.

Epigenomics 2011 Aug;3(4):451-70

Department of Medicine, Hematology/Oncology Division. Room A722, University of California, 1600 Divisadero St, San Francisco, CA 94115-1770, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/epi.11.72DOI Listing
August 2011

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.

Future Oncol 2011 Feb;7(2):263-83

Department of Medicine, Hematology/Oncology Division. University of California-San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.11.2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3127396PMC
February 2011

Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.

Cancer Lett 2009 Aug 30;280(2):184-91. Epub 2009 Jan 30.

Division of Hematology and Oncology, University of California, San Francisco San Francisco, CA 94143, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2008.12.026DOI Listing
August 2009

Estradiol in breast cancer treatment: reviving the past.

JAMA 2009 Aug;302(7):797-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2009.1223DOI Listing
August 2009

Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.

Melanoma Res 2009 Jun;19(3):167-75

Cutaneous Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0b013e328304974cDOI Listing
June 2009

Cognitive functioning in breast cancer survivors: a controlled comparison.

Cancer 2009 Apr;115(8):1776-83

Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.24192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668740PMC
April 2009

Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.

Clin Cancer Res 2009 Apr 24;15(7):2488-96. Epub 2009 Mar 24.

Division of Hematology Oncology, University of California, San Francisco, Divisadero, San Francisco, California 94143-1711, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-1930DOI Listing
April 2009

HDAC2 regulates chromatin plasticity and enhances DNA vulnerability.

Mol Cancer Ther 2009 Apr;8(4):794-801

Experimental Therapeutics Program, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0985DOI Listing
April 2009

Identifying clinically meaningful fatigue with the Fatigue Symptom Inventory.

J Pain Symptom Manage 2008 Nov 20;36(5):480-7. Epub 2008 May 20.

Health Outcomes and Behavior Program, Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpainsymman.2007.11.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2590752PMC
November 2008

Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.

Cancer 2008 Nov;113(10):2646-54

Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.23916DOI Listing
November 2008

Exploring the differential experience of breast cancer treatment-related symptoms: a cluster analytic approach.

Support Care Cancer 2008 Aug 28;16(8):925-33. Epub 2007 Nov 28.

Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and University of South Florida, 12902 Magnolia Drive, MRC-CANCONT, Tampa, FL, 33612, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00520-007-0364-2
Publisher Site
http://dx.doi.org/10.1007/s00520-007-0364-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2892385PMC
August 2008

Activated stat-3 in melanoma.

Cancer Control 2008 Jul;15(3):196-201

Pathology Service, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/107327480801500302DOI Listing
July 2008

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.

Cancer Chemother Pharmacol 2008 Jun 6;62(1):97-109. Epub 2007 Sep 6.

Department of Oncology, Pfizer Global Research and Development, 50 Pequot Avenue MS6025-A3238, New London, CT 06320, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-007-0579-4
Publisher Site
http://dx.doi.org/10.1007/s00280-007-0579-4DOI Listing
June 2008

Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling.

Cancer Res 2008 Mar;68(5):1513-9

Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-07-2822DOI Listing
March 2008

Fatigue after treatment for early stage breast cancer: a controlled comparison.

Cancer 2007 Oct;110(8):1851-9

Health Outcomes and Behavior Program, Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.22993DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646727PMC
October 2007

Physical symptoms/side effects during breast cancer treatment predict posttreatment distress.

Ann Behav Med 2007 Oct;34(2):200-8

Health Outcomes and Behavior Program, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/bf02872674DOI Listing
October 2007

Utility of a cognitive-behavioral model to predict fatigue following breast cancer treatment.

Health Psychol 2007 Jul;26(4):464-72

Health Outcomes and Behavior Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1037/0278-6133.26.4.464DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2383279PMC
July 2007

Discussion of fertility preservation with newly diagnosed patients: oncologists' views.

J Cancer Surviv 2007 Jun;1(2):146-55

Department of Interdisciplinary Oncology, College of Medicine, University of South Florida, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11764-007-0019-9DOI Listing
June 2007

Development of histone deacetylase inhibitors for cancer treatment.

Expert Rev Anticancer Ther 2007 Apr;7(4):583-98

H Lee Moffitt Cancer Center, Experimental Therapeutics Program, Department of Interdisciplinary Oncology, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.7.4.583DOI Listing
April 2007

First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.

Clin Cancer Res 2007 Feb;13(4):1238-45

Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-1539DOI Listing
February 2007

ABCG2 expression, function, and promoter methylation in human multiple myeloma.

Blood 2006 Dec 17;108(12):3881-9. Epub 2006 Aug 17.

H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2005-10-009084DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895461PMC
December 2006

Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.

Mol Cancer Ther 2006 Aug;5(8):2130-7

Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, SRB-2, Tampa, 33612-9416, USA.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-06
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-06-0034DOI Listing
August 2006

Arzoxifene: the development and clinical outcome of an ideal SERM.

Authors:
Pamela N Munster

Expert Opin Investig Drugs 2006 Mar;15(3):317-26

Interdisciplinary Oncology Program, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.15.3.317DOI Listing
March 2006

Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma.

Cancer 2005 Dec;104(11):2499-507

Psychosocial and Palliative Care Program, Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.21482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653200PMC
December 2005

Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.

Clin Cancer Res 2005 Dec;11(23):8467-75

Experimental Therapeutics Program, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-1073DOI Listing
December 2005

In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.

Mol Cancer Ther 2005 Dec;4(12):1993-2000

Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive SRB 22007, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-05-0194DOI Listing
December 2005

Chinese herbal formula, Bing De Ling, enhances antitumor effects and ameliorates weight loss induced by 5-fluorouracil in the mouse CT26 tumor model.

DNA Cell Biol 2005 Jul;24(7):470-5

Department of Oncology, College of Medicine, University of South Florida, Tampa, FL 36112, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/dna.2005.24.470DOI Listing
July 2005

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins.

Cancer Res 2005 May;65(9):3815-22

Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-2478DOI Listing
May 2005

Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.

Clin Cancer Res 2005 Apr;11(8):3009-16

Cutaneous Oncology, Experimental Therapeutics, and Gastrointestinal Oncology Programs, H. Lee Moffitt Cancer Center, Tampa, Florida 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-1722DOI Listing
April 2005

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.

J Cell Biochem 2004 May;92(2):223-37

Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.20045DOI Listing
May 2004